Similarly, D’Incecco et al. observed a strong correlation between PDL1 expression and presence of EGFR mutations in patients with NSCLC, and a significantly longer TTP in EGFR-mutated patients treated with gefitinib or erlotinib with PD-L1 positive disease than in PD-L1 negative disease [32]. Here, CD274 is linked to non-small cell lung carcinoma.